CLAIMS

1. Use of an amylin analog at a therapeutically effective dose:

    (i) of at least 5 μg per kilogram of the subject per day; or

    (ii) that is at or greater than the ED75 dose of the amylin analog, in the preparation of a composition for the treatment of type I diabetes in a human subject.

2. The use of claim 1, further comprising continuously maintaining a concentration of the amylin analog in the subject that is at or greater than the EC75 dose of the amylin analog.

3. The use of claim 1 or claim 2, comprising continuous administration of the amylin analog.

4. The use of claim 1 or claim 2, comprising continuous administration of the amylin analog via an implantable drug delivery device.

5. The use of claim 4, wherein the implantable drug delivery device is an osmotic drug delivery device.

6. The use of claim 1 or claim 2, comprising continuous administration of the amylin analog via a non-implantable drug delivery device.

7. The use of claim 1 or claim 2, comprising continuous administration of the amylin analog via once weekly injection.

8. The use of claim 1 or claim 2, wherein the amylin analog is pramlintide.

9. The use of claim 1 or claim 2, wherein the amylin analog is compound A2 (SEQ ID NO:2).

10. The use of claim 1 or claim 2, further comprising separate administration of an insulin.